ClassID:

96454

C07J1/0025 - CPC Classification

Classification description:

Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane; Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified Esters

Recent Application in this class:
#1
20260151489
2026-06-04

LYMPH DIRECTING PRODRUGS

#2
20260102373
2026-04-16

LYMPH DIRECTING PRODRUGS

#3
20260014170
2026-01-15

PRODRUGS FOR DELIVERY OF TESTOSTERONE TO THE CENTRAL NERVOUS SYSTEM

#4
20260000769
2026-01-01

LYMPH DIRECTING PRODRUGS

#5
20250352510
2025-11-20

LYMPH DIRECTING PRODRUGS

#6
20250325671
2025-10-23

LYMPH DIRECTING PRODRUGS

#7
20250312461
2025-10-09

LYMPH DIRECTING PRODRUGS

#8
20250213522
2025-07-03

LYMPH DIRECTING PRODRUGS

#9
20240050573
2024-02-15

LYMPH DIRECTING PRODRUGS

#10
20220211664
2022-07-07

LYMPH DIRECTING PRODRUGS

#11
20190388434
2019-12-26

(17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use

#12
20190350943
2019-11-21

(17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use

#13
20190105299
2019-04-11

LYMPH DIRECTING PRODRUGS

#14
20180243425
2018-08-30

Lymph directing prodrugs

#15
20180104257
2018-04-19

(17-ß)-3-Oxoandrost-4-En-17-Yl Undecanoate Compositions and Methods of Their Preparation and Use

#16
20170326103
2017-11-16

Lymph directing prodrugs

#17
20170246187
2017-08-31

(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE

#18
20130203718
2013-08-08

PROGESTERONE RECEPTOR ANTAGONISTS AND USES THEREOF

#19
20120214987
2012-08-23

METHODS AND COMPOUNDS FOR PREPARING 3ALPHA-OXYGEN SUBSTITUTED STEROIDS

#20
20120071454
2012-03-22

Steroid compounds and treatment methods

#21
20110118488
2011-05-19

PROCESS FOR OBTAINING 6-ALKYLIDENANDROST-1, 4-DIENE-3-ONE

#22
20110098260
2011-04-28

Steroid compounds and formulations

#23
20110009372
2011-01-13

Compounds and compositions

#24
20100240633
2010-09-23

Cancer treatment methods

#25
20090093638
2009-04-09

Allylic oxidations catalyzed by dirhodium catalysts under aqueous conditions

#26
20080176823
2008-07-24

Breast and prostate cancer treatment method

#27
20080058301
2008-03-06

Formulations

#28
20080021006
2008-01-24

Pharmaceutical compositions

#29
20070275936
2007-11-29

Formulations and Treatment Methods

#30
20070129282
2007-06-07

Pharmaceutical treatments and compositions

#31
20050075322
2005-04-07

Androgenic 7-substituted 11-halogen steroids